Epizyme (EPZM) Misses Q3 EPS by 3c

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.58), $0.03 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $7 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• RenovoRx regains Nasdaq minimum bid price compliance
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand